» Articles » PMID: 2703228

Typical, Dysplastic, Congenital, and Spitz Nevi: a Comparative Immunohistochemical Study

Overview
Journal Hum Pathol
Specialty Pathology
Date 1989 Apr 1
PMID 2703228
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Nevus cell components have been observed in up to 40% of melanomas, but little is known of the pathobiology of these components in relation to their malignant potential. We studied 44 nevi of the typical, dysplastic, congenital, and Spitz types with a battery of monoclonal and polyclonal antibodies that react on formalin-fixed, paraffin-embedded tissues (HMB.45, S-100 protein, RAP-5, epithelial membrane antigen [EMA], and neuron-specific enolase [NSE]) by avidin-biotin immunohistochemical methods. EMA and RAP-5 (which detects the ras oncogene-associated P21 protein) were negative in all cases. Melanoma-specific HMB.45 was strongly reactive with the epidermal component and had a weak to negative reaction with the dermal component in the typical nevi. However, the reaction seen with HMB.45 in the junctional component of dysplastic nevi, congenital nevi, and some Spitz nevi was heterogeneous. One Spitz nevi showed HMB.45 staining in a pattern near to that of melanoma. In contrast to HMB.45, S-100 protein labeled nevomelanocytes, regardless of whether they were within the epidermis or dermis, although, in half of the dysplastic nevi, the reaction was heterogeneous, with some atypical cells failing to stain. But, with cytologically atypical junctional component (dysplastic-appearing), congenital nevi also stained heterogeneously for S-100 protein compared with the dermal component. NSE stained the central component of some Spitz nevi more intensely than the lateral component. Junctional nevomelanocytic subsets of some congenital nevi revealed HMB.45 and S-100 reactivity similar to dysplastic nevi.

Citing Articles

Cutaneous Melanomas: A Single Center Experience on the Usage of Immunohistochemistry Applied for the Diagnosis.

Ricci C, Dika E, Ambrosi F, Lambertini M, Veronesi G, Barbara C Int J Mol Sci. 2022; 23(11).

PMID: 35682589 PMC: 9180684. DOI: 10.3390/ijms23115911.


Genomic Landscape of Spitzoid Neoplasms Impacting Patient Management.

Hillen L, van den Oord J, Geybels M, Becker J, Zur Hausen A, Winnepenninckx V Front Med (Lausanne). 2019; 5:344.

PMID: 30619857 PMC: 6300473. DOI: 10.3389/fmed.2018.00344.


ALK rearrangement and overexpression in epithelioid fibrous histiocytoma.

Doyle L, Marino-Enriquez A, Fletcher C, Hornick J Mod Pathol. 2015; 28(7):904-12.

PMID: 25857825 DOI: 10.1038/modpathol.2015.49.


Expression of activated Akt in benign nevi, Spitz nevi and melanomas.

Kantrow S, Boyd A, Ellis D, Nanney L, Richmond A, Shyr Y J Cutan Pathol. 2007; 34(8):593-6.

PMID: 17640227 PMC: 2665272. DOI: 10.1111/j.1600-0560.2006.00675.x.


Production and characterisation of an antimelanoma monoclonal antibody KBA.62 using a new melanoma cell line reactive on paraffin wax embedded sections.

Al Saati T, Aziza J, Ralfkiaer E, Selves J, Gorguet B, Delsol G J Clin Pathol. 1995; 48(9):826-31.

PMID: 7490315 PMC: 502870. DOI: 10.1136/jcp.48.9.826.